Results 31 to 40 of about 150,928 (204)

Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]

, 2018
Synovial sarcoma (SS) is a recalcitrant subgroup of soft tissue sarcoma (STS). A tumor from a patient with high grade SS from a lower extremity was grown orthotopically in the right biceps femoris muscle of nude mice to establish a patient-derived ...
Dry, Sarah M, Eckardt, Mark A, Eilber, Fritz C, Gainor, Emily, Han, Qinghong, Hayashi, Katsuhiro, Higuchi, Takashi, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kimura, Hiroaki, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miwa, Shinji, Miyake, Kentaro, Miyake, Masuyo, Nelson, Scott D, Oshiro, Hiromichi, Russell, Tara A, Singh, Arun S, Tan, Yuying, Tsuchiya, Hiroyuki, Yamamoto, Norio   +23 more
core   +2 more sources

Soft Tissue Sarcomas

Veterinary Clinics of North America: Small Animal Practice, 1997
The soft tissue sarcomas (STS) constitute approximately 15% of all canine and 7% of all feline skin and subcutaneous tumors. STS are tumors that arise from a variety of mesenchymal tissues. The aggressive nature of STS in cats, especially those tumors occurring after vaccination, suggests that novel therapies should be investigated.
openaire   +4 more sources

Modern Dressings in Prevention and Therapy of Acute and Chronic Radiation Dermatitis—A Literature Review

Pharmaceutics, 2022
Radiotherapy is an integral part of modern oncology, applied to more than half of all patients diagnosed with cancer. It can be used alone or in combination with surgery or chemotherapy.
Konrad Zasadziński, Mateusz Jacek Spałek, Piotr Rutkowski   +2 more
doaj   +1 more source

Ifosfamide with regional hyperthermia in soft-tissue sarcomas [PDF]

, 2003
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival.
Issels, Rolf-Dieter, Schlemmer, M., Wendtner, Clemens-Martin   +2 more
core   +1 more source

BMN673 sensitizes rhabdomyosarcoma tumors to irradiation in vivo [PDF]

, 2020
Bone and soft tissue sarcomas are mesenchymal tumors that occur rarely in adults, representing only 1% of total malignancies, but comprise up to 13% of malignant tumors in children.1 Rhabdomyosarcoma, a soft tissue sarcoma that commonly affects children,
Jacob, Connor
core  

Soft-tissue Sarcomas

Indian Journal of Orthopaedics, 2018
This article discusses the epidemiology, diagnosis, and management of primary soft-tissue sarcomas (STS). These musculoskeletal tumors are a rare and heterogeneous group of malignancies, which are best managed by multidisciplinary teams in specialist sarcoma referral centers.
Vodanovich, Domagoj Ante, M Choong, Peter F   +1 more
openaire   +3 more sources

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G, Matthay, Katherine K, Vo, Kieuhoa T   +2 more
core   +1 more source

BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas [PDF]

, 2016
Bone Morphogenic Protein 2 (BMP2) is a multipurpose cytokine, important in the development of bone and cartilage, and with a role in tumour initiation and progression.
Cassidy, A.P., Cassidy, J.W., Harris, O.B., O’Neill, H.L.   +3 more
core   +3 more sources

Targeting TIMM23 to overcome osteosarcoma chemoresistance

Cell Death and Disease
Osteosarcoma (OS) is a malignant tumor whose chemoresistance severely compromises therapeutic efficacy. This study aims to investigate the molecular mechanism by which TIMM23 mediates M2 polarization of macrophages through mitophagy and regulates TIMM23 ...
Zhiwei Tao, Pingan Zou, Zhengxu Yang, Tao Xiong, Zhi Deng, Qinchan Chen   +5 more
doaj   +1 more source

Tebentafusp (IMCgp100) in the treatment of uveal melanoma — from preclinical evidence to clinical practice

Nowotwory
Tebentafusp (IMCgp100) is a novel bispecific immunotherapy that contains a specifically engineered soluble T-cellreceptor (TCR) capable of recognising the gp100 epitope on the surface of tumour cells presented by human leukocyteantigen-A*02:01 (HLA- A*02:
Piotr Remiszewski, Eryk Siedlecki, Julia Wąż, Kinga Filipek, Agata Pisklak, Wiktor Gaik, Monika Dudzisz-Śledź, Piotr Rutkowski, Anna M. Czarnecka   +8 more
doaj   +1 more source